

**Amendments to the Claims**

Please amend claims 8 and 9 as follows. Please cancel claims 1, 2 and 12-28. Please add claims 29-31.

**Listing of Claims**

**1-2. (Canceled)**

**3. (Original)** The hybridoma cell line with DSMZ accession number DSM ACC2625.

**4. (Original)** The anti-idiotypic antibody expressed by the hybridoma cell line of claim 3.

**5. (Original)** A humanized antibody having the binding specificity of the anti-idiotypic antibody of claim 4.

**6. (Original)** The anti-idiotypic antibody of claim 4, wherein said anti-idiotypic antibody further comprises a detectable agent.

**7. (Withdrawn)** A method of generating an immune response in a mammal against the anti-idiotypic antibody of claim 4, said method comprising immunizing a mammal with the purified antibody of claim 4 in a pharmaceutically acceptable carrier.

**8. (Withdrawn, Currently Amended)** The method of claim ~~[[6]]~~ 7, wherein said anti-idiotypic antibody of claim 4 is humanized prior to immunizing said mammal.

**9. (Withdrawn, Currently Amended)** The method of claim ~~[[6]]~~ 7, wherein said mammal is a non-human mammal.

**10. (Withdrawn)** The method of claim 7 or 8, wherein said immunizing results in cells in said mammal expressing polypeptides that specifically bind to said anti-idiotypic antibody.

**11. (Withdrawn)** The method of claim 10, wherein said polypeptides are antibodies.

**12-28. (Canceled)**

**29. (New)** A humanized anti-idiotypic antibody having the 6 CDRs of the anti-idiotypic antibody expressed by the hybridoma cell line with DSMZ accession number DSM ACC2625, wherein the humanized anti-idiotypic antibody specifically binds a

polypeptide comprising the SC-1 human monoclonal antibody heavy chain sequence set forth in SEQ ID NO:1.

30. (New) The humanized anti-idiotypic antibody of claim 29, where said antibody further comprises a detectable agent.

31. ~~30.~~ (New) A method of generating an immune response in a mammal against the anti-idiotypic antibody of claim 29, said method comprising immunizing a mammal with the purified antibody of claim 29 in a pharmaceutically acceptable carrier.